Neurodegenerative diseases such as Parkinson’s, Alzheimer's and others are increasing worldwide as the population ages. According to Alzheimer's Disease International, more than 50 million persons lived with dementia worldwide in 2020, and roughly 1.2 million people in the United States will develop Parkinson's disease by 2030 according to the NIH.

Neurodegenerative disease is an overarching term for a variety of progressive conditions that affect the neurons of the nervous system, resulting in the damage and death of those cells. These diseases are relentless, often fatal, and affect fundamental functions like moving, breathing, speaking, and thinking.

Vancouver-based InMed Pharmaceuticals Inc. (NASDAQ: INM) – an emerging leader in 

the development and manufacturing of rare cannabinoids for the pharmaceutical and consumer health and wellness industries – reports that it has expanded its pharmaceutical pipeline to investigate rare cannabinoids for their potential in treating neurodegenerative diseases including Alzheimer’s Disease, Parkinson’s Disease and Huntington’s Disease.

In-Depth Research Leading To The Identification Of Rare Cannabinoids For Neurodegenerative Disease

InMed reports that its research team has investigated several cannabinoids to understand and compare their effects in neurodegenerative disease. Its researchers have selected two cannabinoid analogs showing the most promising effects in neuroprotection and enhanced neuronal function to advance to “in vivo” preclinical studies in neurodegenerative disease.

The selected rare cannabinoids demonstrated neuroprotective effects in the affected neurons and promoted neurite outgrowth, according to InMed, signifying the potential for these to enhance neuronal function. …

Full story available on Benzinga.com